Eukaryotic elongation factor 2 kinase confers tolerance to stress conditions in cancer cells

被引:30
|
作者
Zhu, Hongcheng [1 ]
Yang, Xi [1 ]
Liu, Jia [1 ]
Zhou, Lu [2 ,3 ]
Zhang, Chi [1 ]
Xu, Liping [1 ]
Qin, Qin [1 ]
Zhan, Liangliang [1 ]
Lu, Jing [1 ]
Cheng, Hongyan [4 ]
Sun, Xinchen [1 ]
机构
[1] Nanjing Med Univ, Dept Radiat Oncol, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China
[2] Nanjing Med Univ, Nanjing Drum Tower Hosp, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China
[3] Nanjing Med Univ, Clin Coll, Nanjing, Jiangsu, Peoples R China
[4] Nanjing Med Univ, Dept Gen Internal Med, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China
关键词
Eukaryotic elongation factor 2 kinase; eEF2K; eEF2; Cancer; Stress; EEF2; KINASE; BREAST-CANCER; INHIBITION; PHOSPHORYLATION; EXPRESSION; INDUCTION; APOPTOSIS; AUTOPHAGY; TARGET;
D O I
10.1007/s12192-014-0545-0
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Eukaryotic elongation factor 2 (eEF2) is a member of the GTP-binding translation elongation factor family that is essential for protein synthesis. eEF2 kinase (eEF2K) is a structurally and functionally unique protein kinase in the calmodulin-mediated signaling pathway. eEF2K phosphorylates eEF2, thereby inhibiting eEF2 function under stressful conditions. eEF2K regulates numerous processes, such as protein synthesis, cell cycle progression, and induction of autophagy and apoptosis in cancer cells. This review will demonstrate the mechanisms underlying eEF2K activity in cancer cells under different stresses, such as nutrient deprivation, hypoxia, and DNA damage via eEF2 regulation. In vivo, in vitro, and clinical studies indicated that eEF2K may be a novel biomarker and therapeutic target for cancer.
引用
收藏
页码:217 / 220
页数:4
相关论文
共 50 条
  • [1] Eukaryotic elongation factor 2 kinase confers tolerance to stress conditions in cancer cells
    Hongcheng Zhu
    Xi Yang
    Jia Liu
    Lu Zhou
    Chi Zhang
    Liping Xu
    Qin Qin
    Liangliang Zhan
    Jing Lu
    Hongyan Cheng
    Xinchen Sun
    Cell Stress and Chaperones, 2015, 20 : 217 - 220
  • [2] What is the impact of eukaryotic elongation factor 2 kinase on cancer: A systematic review
    Li, Shumin
    Li, Yanjing
    Bai, Yuxian
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2019, 857
  • [3] Eukaryotic Elongation Factor 2 Kinase (eEF2K) in Cancer
    Wang, Xuemin
    Xie, Jianling
    Proud, Christopher G.
    CANCERS, 2017, 9 (12)
  • [4] Targeting eukaryotic elongation factor-2 kinase suppresses the growth and peritoneal metastasis of ovarian cancer
    Erdogan, Mumin Alper
    Ashour, Ahmed
    Yuca, Erkan
    Gorgulu, Kivanc
    Ozpolat, Bulent
    CELLULAR SIGNALLING, 2021, 81
  • [5] Eukaryotic elongation factor 2 kinase as a drug target in cancer, and in cardiovascular and neurodegenerative diseases
    Liu, Rui
    Proud, Christopher G.
    ACTA PHARMACOLOGICA SINICA, 2016, 37 (03) : 285 - 294
  • [6] Eukaryotic elongation factor-2 kinase (eEF2K): a potential therapeutic target in cancer
    Fu, L. L.
    Xie, T.
    Zhang, S. Y.
    Liu, B.
    APOPTOSIS, 2014, 19 (10) : 1527 - 1531
  • [7] Insights Into the Pathologic Roles and Regulation of Eukaryotic Elongation Factor-2 Kinase
    Ballard, Darby J.
    Peng, Hao-Yun
    Das, Jugal Kishore
    Kumar, Anil
    Wang, Liqing
    Ren, Yijie
    Xiong, Xiaofang
    Ren, Xingcong
    Yang, Jin-Ming
    Song, Jianxun
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2021, 8
  • [8] Eukaryotic elongation factor 2 kinase controls proliferation and migration of vascular smooth muscle cells
    Usui, T.
    Nijima, R.
    Sakatsume, T.
    Otani, K.
    Kameshima, S.
    Okada, M.
    Yamawaki, H.
    ACTA PHYSIOLOGICA, 2015, 213 (02) : 472 - 480
  • [9] Regulated stability of eukaryotic elongation factor 2 kinase requires intrinsic but not ongoing activity
    Wang, Xuemin
    Xie, Jianling
    da Mota, Sergio Regufe
    Moore, Claire E.
    Proud, Christopher G.
    BIOCHEMICAL JOURNAL, 2015, 467 : 321 - 331
  • [10] Eukaryotic elongation factor 2 is a prognostic marker and its kinase a potential therapeutic target in HCC
    Pott, Leona L.
    Hagemann, Sascha
    Reis, Henning
    Lorenz, Kristina
    Bracht, Thilo
    Herold, Thomas
    Skryabin, Boris V.
    Megger, Dominik A.
    Kaelsch, Julia
    Weber, Frank
    Sitek, Barbara
    Baba, Hideo A.
    ONCOTARGET, 2017, 8 (07) : 11950 - 11962